0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
The Netherlands, International Julia Travagline 12/16/24 The Netherlands, International Julia Travagline 12/16/24

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands

Read More
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Northeast, Maryland Julia Travagline 11/20/24 Northeast, Maryland Julia Travagline 11/20/24

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Dr. Rosa Nguyen, M.D., Ph.D. – National Cancer Institute, NIH NCI Pediatric Oncology, Bethesda, MD

Read More
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Dr. Ketan Ghaghada, Ph.D. – Baylor College of Medicine, Houston TX

Read More
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
International, Israel Julia Travagline 11/20/24 International, Israel Julia Travagline 11/20/24

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel

Read More
MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition
Northeast, Virginia Julia Travagline 12/8/21 Northeast, Virginia Julia Travagline 12/8/21

MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition

MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition

Virginia Commonwealth University, Richmond, VA

Read More
Arginine methylation as a potential therapeutic target in high-risk neuroblastoma
New York, Northeast Julia Travagline 8/10/21 New York, Northeast Julia Travagline 8/10/21

Arginine methylation as a potential therapeutic target in high-risk neuroblastoma

Arginine methylation as a potential therapeutic target in high-risk neuroblastoma

University of Rochester, Rochester, NY

Read More
Activation of NF-kB in Neuroblastoma Myeloid Cells
Maryland, Northeast Julia Travagline 8/10/21 Maryland, Northeast Julia Travagline 8/10/21

Activation of NF-kB in Neuroblastoma Myeloid Cells

Activation of NF-kB in Neuroblastoma Myeloid Cells

Johns Hopkins University School of Medicine, Baltimore, MD

Read More
Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression
Georgia, South Julia Travagline 8/10/21 Georgia, South Julia Travagline 8/10/21

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Emory University – Winship Cancer Institute, Atlanta, GA

Read More
Disrupting Neuroblastoma Tumor-Initiating Cells
New York, Northeast Julia Travagline 8/9/21 New York, Northeast Julia Travagline 8/9/21

Disrupting Neuroblastoma Tumor-Initiating Cells

Disrupting Neuroblastoma Tumor-Initiating Cells

University of Rochester, Rochester, NY

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark